N/A
N=45
Monitoring of Symptoms and Cognitive Function Using Telehealth
End Stage Liver Disease
Bottom Line
View on ClinicalTrials.gov: NCT03184701 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: Patient Satisfaction — 45 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Telehealth (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Albert Einstein Healthcare Network
- Primary completion
- Aug 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Satisfaction |
45 | — |
Summary
End-Stage Liver Disease (ESLD) is one of the ten leading causes of death in US. It is marked by episodic acute exacerbations of the underlying liver disease which often leads to severe symptoms, poor quality of life, mental deterioration and repeated hospitalizations.
The overall purpose of this project is to introduce a telehealth based intervention (involving remote monitoring of symptoms and cognitive function initiated at the time of discharge of ESLD patients. This will support enhanced clinical care and improve self-management in ESLD population. In addition, it will reduce healthcare utilization, improve medication adherence and overall health outcomes
Eligibility Criteria
Inclusion Criteria
- End Stage Liver Disease with at least 1 or more complications (Hepatorenal Syndrome, Portal Hypertension, Ascites, Hepatic Encephalopathy)
Exclusion Criteria
- Cognitive impairment
- Current psychosis
Data sourced from ClinicalTrials.gov (NCT03184701). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.